SPOTLIGHT: GSK's very public CEO search


GlaxoSmithKline's search for a new CEO has become something of a public spectacle, with three internal contenders vying horse-race style for the spot. Glaxo's retiring CEO has given these three execs special jobs to see how they'd handle the top job, and the company even hired outside consultants to evaluate them. And, as we reported recently, its chairman hashed over the appointment with disgruntled investors. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.